Latest publications Inst. for Cancer Research

Vedeld HM, Pharo H, Sørbø AK, Brandt-Winge S, Five MB, Jeanmougin M, Guldberg P, Wahlqvist R, Lind GE (2024)
Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13639, PubMed 38720532

Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB (2024)
IUIS 2023: yEFIS workshop on career development and code-switching
Eur J Immunol, e2451155 (in press)
DOI 10.1002/eji.202451155, PubMed 38676471

Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13656, PubMed 38671580

Vedeld HM, Pharo H, Sørbø AK, Brandt-Winge S, Five MB, Jeanmougin M, Guldberg P, Wahlqvist R, Lind GE (2024)
Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13639, PubMed 38720532

Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH (2024)
Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
BMC Cancer, 24 (1), 555
DOI 10.1186/s12885-024-12320-8, PubMed 38702616

Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, Rosenquist R, PCM4EU consortium (2024)
High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
J Intern Med (in press)
DOI 10.1111/joim.13785, PubMed 38698538